CardioGenics (OTCMKTS:CGNH – Get Rating) and QuinStreet (NASDAQ:QNST – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.
Analyst Ratings
This is a breakdown of recent ratings for CardioGenics and QuinStreet, as reported by MarketBeat.
Get CardioGenics alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CardioGenics | 0 | 0 | 0 | 0 | N/A |
| QuinStreet | 0 | 1 | 2 | 0 | 2.67 |
QuinStreet has a consensus price target of $13.50, indicating a potential upside of 9.31%.
Institutional and Insider Ownership
91.0% of QuinStreet shares are owned by institutional investors. 41.4% of CardioGenics shares are owned by company insiders. Comparatively, 6.8% of QuinStreet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.Volatility and Risk
CardioGenics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, QuinStreet has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.
Profitability
This table compares CardioGenics and QuinStreet's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CardioGenics | N/A | N/A | N/A |
| QuinStreet | -0.90% | -1.77% | -1.22% |
Valuation & Earnings
This table compares CardioGenics and QuinStreet's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CardioGenics | N/A | N/A | N/A | N/A | N/A |
| QuinStreet | $582.10 million | 1.16 | -$5.25 million | ($0.09) | -137.21 |
CardioGenics has higher earnings, but lower revenue than QuinStreet.
About CardioGenics
(Get Rating)
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.
About QuinStreet
(Get Rating)
QuinStreet, Inc., an online performance marketing company, provides customer acquisition services for its clients in the United States and internationally. The company offers online marketing services to its clients in the form of qualified clicks, leads, calls, applications, or customers through its websites or third-party publishers. It provides its services in various verticals, such as financial services and home services. The company was incorporated in 1999 and is headquartered in Foster City, California.
Receive News & Ratings for CardioGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CardioGenics and related companies with MarketBeat.com's FREE daily email newsletter.